Bank of China Securities released a research report on April 18 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) The company released the 2023 report and the 2024 quarterly report, and the performance maintained steady growth. The company continues to increase investment in R&D, innovative products are frequent, and the R&D pipeline is progressing rapidly, which is expected to drive steady growth on the revenue side in the future; 2) performance will maintain steady growth under the influence of multiple negative growth factors; 3) continue to increase innovation efforts and continue to be approved to promote the company's innovation and transformation; 4) clinical trials of innovative drugs are progressing smoothly, steadily promoting the company's internationalization process. (Mainichi Keizai Shimbun)